Ibrutinib is a Burton tyrosine kinase inhibitor (BTKi) approved for the treatment of several
hematologic malignancies. Analyze skin adverse events (SAE). All the patients treated with …

Ibrutinib is a Bruton tyrosine kinase inhibitor used to treat many hematologic conditions,
most commonly B‐cell lymphomas and leukemias. Reportedly, skin rash is an adverse event …

Introduction Ibrutinib is an oral inhibitor of Bruton's tyrosine kinase that is used for a variety of
B cell hematological malignancies. Skin and subcutaneous tissue manifestations have been …

Background Ibrutinib, a Bruton's tyrosine kinase inhibitor has reformed the treatment of
various B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma …

Background Ibrutinib is an oral inhibitor of Bruton tyrosine kinase that is approved by the
United States Food and Drug Administration for several lymphoproliferative disorders and …

Ibrutinib is an oral covalent inhibitor of the Bruton's tyrosine kinase pathway and is approved
for the treatment of B-cell malignancies including chronic lymphocytic leukaemia, mantle cell …

Waldenstrom's macroglobulinamia (WM) is a rare malignant lymphoproliferative disorder,
characterized by monoclonal IgM paraproteinemia and neoplastic proliferation of malignant …

The scope of dermatologic adverse events to ibrutinib has not been systematically
described. We sought to determine the incidence and severity of ibrutinib-associated …

Abstract Introduction: Ibrutinib is a Bruton tyrosine kinase inhibitor approved for previously
treated chronic lymphocytic leukemia (CLL), CLL with del (17p), previously treated mantle …

In this issue of Acta Haematologica, Schamroth Pravda et al.[1] describe a 37-year-old male
treated with ibrutinib for advanced mantle cell lymphoma who developed fatal central …